DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Gen ADCs Built on DualityBio’s DUPAC Novel-Payload Platform

“As topoisomerase inhibitor–based ADCs achieve broad clinical success and move into earlier lines of therapy, a growing unmet medical need is emerging for patients whose tumors are resistant or refractory to this payload class. We built DUPAC to help address this challenge with a family of next-generation payloads designed to overcome resistance and enable each ADC program to expand the breadth of the underlying tumor biology. By combining DualityBio’s payload innovation and early-stage global clinical development capabilities with Genentech’s deep oncology expertise and worldwide development reach, we can advance these programs with greater speed and scale and bring differentiated medicines to more patients around the world,” said Dr. John Zhu, Founder and Chief Executive Officer of DualityBio.

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib